

# Characterization of NDM-5 Carbapenemase-Encoding Gene ( $bla_{\text{NDM-5}}$ ) – Positive Multidrug Resistant Commensal *Escherichia coli* from Diarrheal Patients

Goutam Chowdhury<sup>1,2</sup>, Thandavarayan Ramamurthy<sup>1</sup>, Bhabatosh Das<sup>3</sup>, Debjani Ghosh<sup>1</sup>, Keinosuke Okamoto<sup>2</sup>, Shin-ichi Miyoshi<sup>2,4</sup>, Shanta Dutta<sup>1</sup>, Asish K Mukhopadhyay<sup>1</sup>

<sup>1</sup>Division of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, India; <sup>2</sup>Collaborative Research Centre of Okayama University for Infectious Diseases, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, India; <sup>3</sup>Department of Infection and Immunology, Translational Health Science and Technology Institute, Faridabad, India; <sup>4</sup>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Correspondence: Goutam Chowdhury; Asish K Mukhopadhyay, Division of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases, P-33, CIT Road, Scheme XM, Beliaghata, Kolkata, 700010, India, Email [goutambiotech@gmail.com](mailto:goutambiotech@gmail.com); [asish\\_mukhopadhyay@yahoo.com](mailto:asish_mukhopadhyay@yahoo.com)

**Purpose:** The multidrug resistance Enterobacteriaceae cause many serious infections resulting in prolonged hospitalization, increased treatment charges and mortality rate. In this study, we characterized  $bla_{\text{NDM-5}}$ -positive multidrug resistance commensal *Escherichia coli* (CE) isolated from diarrheal patients in Kolkata, India.

**Methods:** Three CE strains were isolated from diarrheal stools, which were negative for different pathogroups of diarrheagenic *E. coli* (DEC). The presence of carbapenemases encoding genes and other antimicrobial resistance genes (ARGs) was detected using PCR. The genetic arrangement adjoining  $bla_{\text{NDM-5}}$  was investigated by plasmid genome sequencing. The genetic relatedness of the strains was determined by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) methods.

**Results:** In addition to colistin, the  $bla_{\text{NDM-5}}$ -positive CE strains showed resistance to most of the antibiotics. Higher MICs were detected for ciprofloxacin (>32 mg/L) and imipenem (8 mg/L). Molecular typing revealed that three CE strains belonged to two different STs (ST 101 and ST 648) but they were 95% similar in the PFGE analysis. Screening for ARGs revealed that CE strains harbored *Int-1*,  $bla_{\text{TEM}}$ ,  $bla_{\text{CTX-M3}}$ ,  $bla_{\text{OXA-1}}$ ,  $bla_{\text{OXA-7}}$ ,  $bla_{\text{OXA-9}}$ , *tetA*, *strA*, *aadA1*, *aadB*, *sul2*, *floR*, *mph(A)*, and *aac(6')-Ib-cr*. In conjugation experiment, transfer frequencies ranged from  $2.5 \times 10^{-3}$  to  $8.4 \times 10^{-5}$ . The  $bla_{\text{NDM-5}}$  gene was located on a 94-kb pNDM-TC-CE-89 type plasmid, which is highly similar to the IncFII plasmid harboring an IS26-IS30- $bla_{\text{NDM-5}}$ - $ble_{\text{MBL}}$ -*trpF*-*dsbd*-IS91-*dhps* structure.

**Conclusion:** To the best of our knowledge, this is the first report on carbapenem resistance involving the  $bla_{\text{NDM-5}}$  gene in CE from diarrheal patients. The circulation of  $bla_{\text{NDM-5}}$  gene in CE is worrisome, since it has the potential to transfer  $bla_{\text{NDM-5}}$  gene to other enteric pathogens.

**Keywords:** antimicrobial resistance, carbapenem-resistance, commensal *E. coli*, plasmid;  $bla_{\text{NDM-5}}$

## Introduction

The emergence and rapid spread of carbapenemases-producing Enterobacteriaceae is a serious public-health concern because carbapenems are the last resort antibiotics to treat extensively multidrug-resistant (MDR) bacterial infections.<sup>1</sup> Amongst the newly emerging carbapenemases-producers, NDM is very important due to its increased MDR phenotype and rapid global dissemination with frequent allelic variations.<sup>2</sup> Since its first discovery in 2008, more than 20 variants of NDM have been identified in different bacterial species spread across different countries.<sup>3–5</sup> In 2011, the NDM-5 was first identified from an MDR *E. coli* isolated in the United Kingdom from a patient who had been previously treated in India.<sup>6</sup> The NDM-5 varied from NDM-1 by only two amino acid replacements at positions 88 (Val → Leu) and 54 (Met

→ Leu).<sup>6</sup> NDM-5-producing Enterobacteriaceae has been reported worldwide, including in Algeria,<sup>7</sup> Australia,<sup>8</sup> China,<sup>9</sup> Egypt,<sup>10</sup> India,<sup>11</sup> Italy,<sup>12</sup> Mali,<sup>13</sup> South Korea,<sup>14</sup> Spain,<sup>15</sup> and United States.<sup>16</sup>

The mechanism for dissemination and transmission of *bla*<sub>NDM-5</sub> among Enterobacteriaceae is primarily associated with the transfer of plasmids or the transposon-related mobile genetic elements.<sup>17</sup> The *bla*<sub>NDM-5</sub> has been reported worldwide with numerous incompatibility-type plasmid groups and the most prevalent being IncFIA and IncFK in India,<sup>18</sup> IncFII in the United States,<sup>16</sup> IncF and IncX3 in China,<sup>9</sup> IncFIA/B and IncX3 in Korea,<sup>14</sup> and IncFIA and IncFIB in Egypt.<sup>10</sup>

*E. coli* is the most common pathogen associated with community acquired infections. MDR in *E. coli* has become an increasing problem in human health management.<sup>19</sup> Acquisition of the gene encoding NDM by *E. coli* isolates is an important health issue due to its fast spread across the globe and also in other Gram-negative bacteria.<sup>20</sup> This emerging trend is directly associated with an increased use of carbapenems during the treatment of several infectious diseases.<sup>21</sup> In this study, we report on the incidence of the NDM-5-producing commensal *E. coli* isolated from diarrheal patients in Kolkata, India. To the best of our knowledge, this is the first report on CE strains producing NDM-5 carbapenemases. The present study characterized *bla*<sub>NDM-5</sub> identified in CE isolated from diarrheal patients and its dissemination through conjugative plasmid into other enteric bacteria.

## Materials and Methods

### Clinical Specimens

In this study, stool specimens collected from acute diarrheal patients hospitalized at the Infectious Diseases Hospital, Kolkata, India, were tested for the identification of enteric pathogens. Patients who excreted >3 loose or liquid stools per day with no, some or severe dehydration were considered to have diarrhea.<sup>22</sup> Fecal specimens were collected in McCartney bottles using sterile catheters or as rectal swab in Cary Blair transportation medium and processed in the laboratory within 2 hrs for common enteric pathogens.<sup>23</sup>

### Identification and Isolation of Commensal *E. coli*

For identification and isolation of *E. coli*, fecal specimens were inoculated on MacConkey agar (Difco, USA) and incubated at 37°C for 16–18 hrs. Three typical colonies per sample from MacConkey agar plate (including both lactose fermenting and non-lactose fermenting colonies) were picked and sub-cultured on Luria Bertani agar (LBA, Difco, USA) plates. A small portion of cultures was taken from LBA and tested for indole-production by adding the Kovacs reagent. Colour changes to pink were recorded positive and additionally tested in triple sugar iron agar for typical *E. coli*. For further confirmation, all the isolates were individually tested on a Vitek-2 compact system (bioMérieux). Indole, biochemical and Vitek-2 compact-positive bacterial cultures from each of the three colonies plated on LBA plates were taken and mixed with 500 µL of sterile water or phosphate-buffer saline in 1.5 mL microfuge tubes. The bacterial suspension was boiled in a water bath for 10 min and then kept on ice for snap chill for 5 min. Bacterial suspensions were centrifuged at 8000 rpm for 10 min and the supernatants were used as DNA templates in the multiplex PCR for the detection of virulence marker genes, such as CVD432 and *aaiC* (enteroaggregative *E. coli*), *eae* and *bfpA* (enteropathogenic *E. coli*), *elt* and *est* (enterotoxigenic *E. coli*).<sup>24</sup> Simplex PCR was also performed for the detection of Shiga toxin-producing *E. coli*, and/or enterohemorrhagic *E. coli* (*stx1*, *stx2*), enteroinvasive *E. coli* (EIEC) (*ipaH*) and cytolethal distending toxin (*cdt*) gene for *E. albertii*.<sup>25</sup> We defined commensal *E. coli* when the tested colonies were negative for all the above virulence marker genes.

### Antimicrobial Susceptibility Testing (AST)

AST was performed in accordance with the Clinical and Laboratory Standards Institute<sup>26</sup> by disc diffusion method using commercially available discs (Becton Dickinson Company, USA) namely, ampicillin (AMP), ceftriaxone (CRO), cefotaxime (CTX), ceftazidime (CAZ), chloramphenicol (CHL), nalidixic acid (NA), ciprofloxacin (CIP), ofloxacin (OFX), norfloxacin (NOR), meropenem (MEM), streptomycin (STR), erythromycin (E), azithromycin (AZM), gentamicin (GM), tetracycline (TET), doxycycline (D), trimethoprim/sulfamethoxazole

(SXT). In addition, MICs against ampicillin, azithromycin, ceftriaxone, cefotaxime, erythromycin, gentamicin, meropenem, and sulfamethoxazole/trimethoprim were determined using the E-test (AB Biodisk, Sweden), according to the manufacturer's instructions. Detection of the extended spectrum  $\beta$ -lactamase (ESBL) activity was made using the combination disc test (cefotaxime, 30  $\mu$ g; ceftazidime, 30  $\mu$ g; with and without clavulanic acid, 10  $\mu$ g). Strains were considered as ESBL positive, if they exhibit >5 mm increase in the size of the zone of inhibition of the  $\beta$ -lactamase inhibitor combinations in comparison to a third-generation cephalosporin without the  $\beta$ -lactamase inhibitor. *E. coli* ATCC25922 was served as control in antimicrobial susceptibility testing.

## “O” Serogrouping of *E. coli* Isolates

The “O” serogrouping of *E. coli* was made using an *E. coli* “O” serotyping kit by slide agglutination test in accordance with the manufacturer's instructions (Denka-Seiken Co. Ltd., Japan). This kit consists of eight “O” polyvalent and 43 monospecific antisera.

## Molecular Typing

Pulsed-field gel electrophoresis (PFGE) was performed using a CHEF-Mapper (Bio-Rad, Hercules, USA) based on Pulse-Net standardized protocol.<sup>27</sup> PFGE was made by *Xba*I-digested genomic DNA of *E. coli* species. PFGE images were saved by using a Gel Doc XR system (Bio-Rad). The PFGE gel images were analysed using the BioNumerics software version 5.0 (Applied Maths, Sint-Martens-Latem, Belgium) by normalizing and aligning the peaks of the *Salmonella enterica* serovar Braenderup H9812 size standard. The banding pattern similarity and the clustering correlation coefficients were calculated by comparison of the dice-coefficient and UPGMA, respectively. Multilocus sequence typing (MLST) was also carried out for molecular typing. Bacterial genomic DNA was extracted from the CE strains by DNA mini kit (Qiagen, Germany). Seven housekeeping genes (*adh*, *icd*, *fumC*, *gyrB*, *mdh*, *purA* and *recA*) were amplified by PCR,<sup>28</sup> and the amplicons were submitted for DNA sequencing. ST analysis was done according to the protocols specified at the *E. coli* MLST website (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>).

## Antimicrobial Resistance Gene (ARGs) Screening

Different ARGs were screened by PCR, and the positive amplicons were confirmed by DNA sequencing. The PCR assays targeted AMR genes for carbapenemases (*bla*<sub>NDM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>KPC</sub>, *bla*<sub>OXA-48</sub>, *bla*<sub>SIM</sub>, and *bla*<sub>VIM</sub>), gentamicin (*aadB*), streptomycin (*aadA1* and *strA*), chloramphenicol (*catA1*, *floR*), extended-spectrum  $\beta$ -lactamase (*bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>PSE4</sub>, *bla*<sub>CTXM-3</sub>, *bla*<sub>OXA-1</sub>, *bla*<sub>OXA-7</sub> and *bla*<sub>OXA-9</sub>), ciprofloxacin [*aac(6')-Ib-cr*], and macrolides {*mph(A)*, *mph(B)*, *erm(A)*, *erm(B)*}. Simplex PCR was carried out as described previously.<sup>29</sup>

## Mutations in the Quinolone Resistance-Determining Regions (QRDRs)

The chromosomal genes *gyrA* and *parC* were amplified by PCR for the QRDRs and sequenced to analyse the potential mutations. We used published primers for the amplification of *gyrA* and *parC* genes.<sup>30</sup>

## Conjugation Assay

To test the transfer of the *bla*<sub>NDM-5</sub>, conjugation assay was made using NDM-5 positive commensal *E. coli* (CE-89) as donor with two different recipients, namely *E. coli* J53 (sodium azide resistant) and *Salmonella enterica* serovar Bareilly. In brief, overnight seed cultures of the bacteria were inoculated in LB broth for late-exponential phase culture. Cell density of bacterial culture was adjusted to  $1.5 \times 10^8$  cells/mL. Both the cultures of donor and recipient were mixed (at the ratio of 1:2) in 5 mL of LB broth and kept at 37°C for overnight. Several selective media with antibiotics were used to recover *bla*<sub>NDM-5</sub> positive transconjugants (TC). MacConkey agar containing both sodium azide (100  $\mu$ g/mL) and meropenem (5  $\mu$ g/mL) was used to select TC of *E. coli* J53 (TC-*E. coli* J53). Similarly, transconjugants of *Salmonella* (TC-*Salmonella*) were obtained by selecting on xylose lysine deoxycholate (XLD, Difco) containing meropenem (5  $\mu$ g/mL). Putative transconjugants harboring *bla*<sub>NDM-5</sub> were detected by PCR analysis followed by amplicon sequencing. The conjugation frequency was calculated as the number of transconjugants per recipient cell.

## Plasmid Profiling

Plasmid DNA was extracted from the CE strains and transconjugants using a modified Kado and Liu method.<sup>31</sup> The plasmid DNA of *E. coli* V517 and J53 pMG252 were used as molecular weight markers for determining the molecular weight of plasmid DNAs of CE strains and the transconjugants. Plasmid incompatibility of major groups was determined by using PCR-based replicon typing.<sup>32</sup>

## Plasmid Sequence Analysis

Plasmid carrying *bla*<sub>NDM-5</sub> was extracted from the TC-CE-89 using a QIAGEN plasmid midi kit according to the manufacturer's instructions (QIAGEN). The complete plasmid sequence was obtained using an Illumina HiSeq platform. The DNA library was prepared for the pair end sequencing. The derived reads were subsequently trimmed and assembled de novo using the CLC genomics work bench. The plasmid sequences were annotated by Prokaryotic Dynamic Programming Gene finding Algorithm (Prodigal tool v.2.6.3). The open reading frames were compared using BLAST against the non-redundant protein database. Different ARGs in the plasmid were identified by comparing the ORFs with the genes of the Comprehensive Antibiotic Resistance Database (CARD). For the ARGs, we selected the thresholds of identity >70% and subject coverage >90%. The circular map of the pNDM-TC-CE-89 plasmid was generated using the Snap Gene server.

## Nucleotide Sequence

The complete nucleotide sequences of plasmid pNDM-TC-CE-89 were submitted to GenBank accession number MZ892875.

## Results

### Isolation, Identification and Serotyping of *E. coli* from Stool Specimens

Three carbapenem-resistant CE strains were isolated from three different hospitalized acute diarrheal patients in 2015. All three strains were confirmed as *E. coli* using biochemical and Vitek-2 compact system. As confirmed in the multiplex PCR assay, these CE strains did not harbour any virulence encoding genes specific to DEC. Serological results showed that the "O" antigen of the CE strains is different. One CE strain was untypable (ONT) and the other strains belonged to O167 and O86a (Table 1).

### Antimicrobial Susceptibility Testing and MIC

All the three CE strains shared the similar AMR profile. As shown in Table 1, CE strains are resistant to meropenem, ciprofloxacin, nalidixic acid, norfloxacin, ampicillin, ofloxacin, tetracycline, ceftriaxone, sulfamethoxazole/trimethoprim, streptomycin, ceftazidime, erythromycin, chloramphenicol, gentamicin, and cefotaxime but remained susceptible to doxycycline and colistin. CE displayed a higher MIC value for most of the antibiotics (Table 2). The modified Hodge test and imipenem-EDTA double-disc synergy test confirmed the production of metallo- $\beta$ -lactamases (MBLs) by the CE strains. Carbapenemase gene screening revealed that all the CE strains harbored the *bla*<sub>NDM-5</sub> gene that was further confirmed by amplicon sequencing. The sequence of the *bla*<sub>NDM-5</sub> gene exhibited 100% homology with previously reported sequences.<sup>6</sup>

### PCR for Antimicrobial Resistance Genes and QRDRs

The results of ARGs detected in the CE are shown in Table 1. Class-1 integron was identified in the *bla*<sub>NDM-5</sub> positive CE strains. In addition to *bla*<sub>NDM-5</sub>, CE were positive for  $\beta$ -lactamase-encoding genes *bla*<sub>TEM</sub>, *bla*<sub>CTX-M3</sub>, *bla*<sub>OXA-1</sub>, *bla*<sub>OXA-7</sub> and *bla*<sub>OXA-9</sub>; tetracycline resistance marker gene *tet(A)*, streptomycin-encoding gene *strA* and *aadA1*; gentamicin encoding gene *aadB*; sulfonamides encoding gene *sul2*; chloramphenicol encoding gene *floR*, macrolide resistance phosphotransferase encoding gene *mph(A)*; and ciprofloxacin modifying enzyme-encoding gene *aac(6')-Ib-cr* (amino glycoside actetyltransferase). Plasmid-mediated quinolone resistance (PMQR) *qnrB* gene was detected only in CE-89.

**Table 1** Characterization of AMR and Their Encoding Genes in NDM-5-Producing Commensal *E. coli*

Strain ID	"O" Serotype	MLST Sequence Typing	Resistance Profile	Antibiotic Resistance Gene	Amino acid Substitutions in the QUINOLONE Resistance-Determining Region	
					GyrA	ParC
CE-88	167	101	NA,CIP,NOR,OFX,TE, MEM,AM,CRO,SXT,S, CAZ,E,C,GM,CTX,AZM	<i>Int-1, bla<sub>NDM</sub>, bla<sub>TEM</sub>, bla<sub>CTX-M3</sub>, bla<sub>OXA-1</sub>, bla<sub>OXA-7</sub>, bla<sub>OXA-9</sub>, tetA, strA, aadA1, aadB, sul2, floR, mph(A), aac(6')-Ib-cr</i>	Ser 83 Leu Asp 87 Asn	Ser 80 Ile
CE-89	86a	101	NA,CIP,NOR,OFX,TE, MEM,AM,CRO,SXT,S, CAZ,E,C,GM,CTX,AZM	<i>Int-1, bla<sub>NDM</sub>, bla<sub>TEM</sub>, bla<sub>CTX-M3</sub>, bla<sub>OXA-1</sub>, bla<sub>OXA-7</sub>, bla<sub>OXA-9</sub>, tetA, strA, aadA1, qnrB, aadB, sul2, floR, mph(A), aac(6')-Ib-cr</i>	Ser 83 Leu Asp 87 Asn	Ser 80 Ile
CE-93	Untypable	648	NA,CIP,NOR,OFX,TE, MEM,AM,CRO,SXT,S, CAZ,E,C,GM,CTX,AZM	<i>Int-1, bla<sub>NDM</sub>, bla<sub>TEM</sub>, bla<sub>CTX-M3</sub>, bla<sub>OXA-1</sub>, bla<sub>OXA-7</sub>, bla<sub>OXA-9</sub>, tetA, strA, aadA1, aadB, sul2, floR, mph(A), aac(6')-Ib-cr</i>	Ser 83 Leu Asp 87 Asn	Ser 80 Ile

**Abbreviations:** AM, ampicillin; AZM, azithromycin; C, chloramphenicol; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CTX, cefotaxime; E, erythromycin; GM, gentamicin; MEM, meropenem; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; S, streptomycin; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline.

**Table 2** Minimum Inhibitory Concentration (MIC) of Donor, Recipients, and Transconjugants

Strain ID	Bacteria	Resistance Profile	*Frequency of Transfer	MIC (µg/mL)						
				MEM	SXT	CRO	GM	AM	CTX	AZM
CE-89	<i>E. coli</i> (Donor)	NA,CIP,NOR,OFX,TE, MEM,AM, CRO,SXT,S,CAZ,E,C,GM, CTX,AZM	-	32	>32	>256	>256	>256	>16	>256
J53	<i>E. coli</i> (Recipient)	AZD	-	0.064	0.047	0.75	0.25	1.5	0.064	0.75
TC- J53	<i>E. coli</i> (Transconjugant)	AM, MEM, CRO, CAZ, E, SXT, CTX, GM, AZM, AZD	$8.4 \times 10^{-5}$	4	>32	>256	>256	>256	>16	>256
BCH 0704	<i>Salmonella</i> Bareilly (Recipient)	-	-	0.064	0.50	0.50	0.38	0.50	0.064	0.75
TC-BCH 0704	<i>Salmonella</i> Bareilly (Transconjugant)	AM, MEM, CRO, CAZ, E, SXT, CTX, GM, AZM	$2.5 \times 10^{-3}$	4	>32	>256	>256	>256	>16	>256


**Notes:** \*Frequency of transfer was calculated as number of transconjugants per donor cell.

**Abbreviations:** AM, ampicillin; AZM, azithromycin; AZD, azide; C, chloramphenicol; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CTX, cefotaxime; E, erythromycin; GM, gentamicin; MEM, meropenem; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; S, streptomycin; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline.

Additionally, three strains had amino acid substitutions in the QRDRs, ie, in GyrA (Ser 83 Leu and Asp 87 Asn) and ParC (Ser 80 Ile) (Table 1).

## MLST and PFGE

In the MLST sequence analysis, CE-88 and CE-89 were identified as ST101 Cplx (*adh* allele 43; *fumC* allele 41; *gyrB* allele 15; *icd* allele 18; *mdh* allele 11; *purA* allele 7 and *recA* allele 6), whereas CE-93 was identified as ST648 Cplx (*adh* allele 92; *fumC* allele 4; *gyrB* allele 87; *icd* allele 96; *mdh* allele 70; *purA* allele 58 and *recA* allele 2, Table 1). PFGE revealed that isolates had ~90–95% similarity, suggesting that the three CE strains are genetically related clones (Figure 1).



**Figure 1** *XbaI* restriction patterns of genomic DNA of CE strains, Kolkata, India. Dendrogram was generated by using the unweighted pair group with the arithmetic mean method.

## Plasmid Characterisation and Conjugation


The  $bla_{NDM-5}$  harboring CE carried multiple plasmids ranging from 5 kb to 95 kb. In the transconjugants, only a single plasmid of size ~94 kb was detected. Plasmid harboring the  $bla_{NDM-5}$  was transferable from CE-89 to a laboratory strain *E. coli* J53 and a clinical isolate of *Salmonella enterica* serovar Bareilly. While using *E. coli* J53 as recipients, the conjugation frequency was higher ( $\sim 10^5$  transconjugants per donor cell) than *S. Bareilly* ( $\sim 10^3$  transconjugants per donor cell) (Table 2). TC-*E. coli* J53 and TC-*S. Bareilly* acquired resistance to ampicillin, meropenem, ceftriaxone, ceftazidime, erythromycin, sulfamethoxazole/trimethoprim, cefotaxime, gentamicin and azithromycin, indicating the possibility that the  $bla_{NDM-5}$  plasmid carried the corresponding resistance to these antimicrobials. However, the CT-*E. coli* J53 and TC-*S. Bareilly* were susceptible to quinolone, fluoroquinolones and tetracycline. The MIC values of antimicrobials of donor and recipient are shown in Table 2. For meropenem, the MIC value of transconjugants was 4 mg/L, but higher MIC values were observed for other antibiotics.

## Plasmid Sequence Analysis

The plasmid typing has identified that the CE harbours IncFII replicon. Considering that the  $bla_{NDM-5}$  harbored transferable plasmids of the same size and incompatibility group, we have chosen pNDM-TC-CE-89 as a representative for whole-genome sequencing to identify the genetic background and the flanking regions of  $bla_{NDM-5}$ . This plasmid was identified to comprise several types of genes, including ARGs, mobile elements, and putative genes, genes encoding proteins that control plasmid replication, stability and transfer. Moreover, the sequence alignments based on BLAST revealed that pNDM-TC-CE-89 has 99% nucleotide identity with previously reported  $bla_{NDM-5}$  harboring plasmid of *E. coli* (99.9% sequence similarity, 100% query coverage; AP018144.1)<sup>33</sup> including the complete array of genes for replication, partitioning, type IV conjugative transfer system, maintenance and stabilization.

The nucleotide sequence length of pNDM-TC-CE-89 was 94,224-bp with an average GC content of 53%, which is slightly higher than that of *E. coli* (~50%). In addition, we observed that the plasmid has harbored different classes of ARGs, which include dihydrofolate reductase (*dhfR*), aminoglycoside 3'-nucleotidyltransferase (*aadA*), Class A  $\beta$ -lactamase ( $bla_{TEM}$ ), 23S rRNA dimethyl transferase (*ermB*) and macrolide 2'-phosphotransferase (*mphA*) family. The genes responsible for other antimicrobial resistance were not detected in this plasmid (Figure 2). The ARGs BLAST sequence alignments and the most similar nucleotide sequences to those of the previously reported plasmid have been shown in Table 3.

The  $bla_{NDM-5}$  within pNDM-TC-CE-89 was situated in a complex integron, connected by two IS26 sequences having an IS91 element and a class 1 integron with the *intI1* gene truncated by one of the IS26 copies and the *aadA2-dfrA12* resistance gene cassettes. The flanking genetic structure of the  $bla_{NDM-5}$  of pNDM-TC-CE-89 plasmid composed of an IS30 and IS26 located upstream, and the genes  $ble_{MBL}$  (bleomycin resistance gene), *trpF* (phosphoribosyl anthranilate isomerase), *dsbd* (DsbD superfamily protein), IS91 and *dhps* (dihydropteroate synthase) in downstream (IS26-IS30- $bla_{NDM-5}$ - $ble_{MBL}$ -*trpF*-*dsbd*-IS91-*dhps*) (Figure 3).



**Figure 2** Schematic representation and comparison of the sequences of different antimicrobial resistance encoding genes and their association with mobile genetic elements of *E. coli* (accession no. AP018144.1), (*K. pneumoniae* (accession no. CP024840.1) and commensal *E. coli* (CE-89) strains harboring *bla*<sub>NDM-5</sub>. Arrow lengths are proportionate to the lengths of the genes or open reading frames. Genetic structure of CE NDM isolates was identified the link between resistance genes and mobile genetic element. *trpF*: phosphoribosylanthranilate isomerase gene; IS26: IS26 transposase; *IntI1*: class I integron integrase *IntI1*; *dfrA12*: dihydrofolate reductase; *aadA2*: aminoglycoside resistance protein; SMR: quaternary ammonium compound efflux SMR transporter QacE delta 1; Dhps: dihydropteroate synthase. IS91: IS91 family transposase; Dsbd: Thiol: disulfide interchange protein DsbD; PRAI: phosphoribosylanthranilate isomerase; *ble*<sub>MBL</sub>: bleomycin resistance protein; *bla*<sub>NDM-5</sub>: subclass B1 metallo- $\beta$ -lactamase NDM-5; IS30: Transposase-like protein, IS30 family; *bla*<sub>TEM</sub>:  $\beta$ -lactamase; *tnpR*: Transposon Tn3 resolvase, *mphA*: macrolide 2'- phosphotransferase.

## Discussion

The emergence of NDM-producing Enterobacteriaceae is an increasing threat to global health. The *bla*<sub>NDM</sub> harboring strains confer resistance to most of the  $\beta$ -lactams and also express resistance to cephalosporins, quinolones, and aminoglycosides with different ARGs, which allows pathogens to become MDR.<sup>34</sup> AMR is not restricted only to pathogenic bacteria, but the commensal gut bacteria also play a role in harboring and transmission of ARGs. *E. coli* is commonly found as a commensal gut microbiota and considered as a reservoir of acquired AMR determinants.<sup>35</sup> Since *bla*<sub>NDM-5</sub> was first identified in the UK, many bacterial species harboring this gene have emerged in several countries.<sup>36</sup> Although NDM-5-producing strains appear to be a common NDM variant, they remain less compared to NDM-1-variant.<sup>37</sup> In India, different sequence types (STs) of NDM-5 producing *E. coli* and other bacterial strains have been detected from clinical and other sources. The *E. coli* isolates harbour the *bla*<sub>NDM-5</sub> gene in either plasmids or the transposon-related mobile genetic elements. Different incompatibility groups of plasmids belonging to the IncF, IncFII IncX3, K and FrepB are reported to carry the *bla*<sub>NDM-5</sub> gene.<sup>11,38,39</sup> Furthermore, *E. coli* harbouring the *bla*<sub>NDM-5</sub> found on IncX3 plasmids isolated from patients who travelled from India to Australia and Denmark, suggesting the origin of NDM-5 with STs 648 and 1284, respectively.<sup>8,40</sup> In addition, the NDM-5-producing *E. coli* has been identified from fresh fish and mastitic milk samples in India.<sup>41,42</sup> In this study, the three NDM-5-producing CE displayed close genetic similarity as evidenced from PFGE and plasmid typing and AMR profile.


CE strains harboring *bla*<sub>NDM-5</sub> were typed as ST101 and ST648. ST101 of *E. coli* producing NDM-5 in China and Myanmar were documented as an epidemic clone of substantial public health concern carrying plasmids associated with ARGs.<sup>43</sup> *E. coli* ST648 was first reported in India and UK<sup>6</sup> and has also been sporadically detected worldwide.<sup>8-12</sup> The ST648 isolate detected in this study was highly resistant to several different classes of antimicrobial agents. A similar observation was made in earlier studies.<sup>8,43</sup>

Fluoroquinolone resistance in Enterobacteriaceae is primarily due to mutations in the QRDRs of DNA gyrase and topoisomerase IV. The two enzymes are encoded by the *gyrA* for DNA gyrase (topoisomerase II) and *parC* for

**Table 3** Characteristics of Plasmid Encoded AMR and Other Genes in Different Bacterial Species

Gene Name	Size (bp)	GC content (%)	Similar Gene in Other Bacterial Species	Similarity		Accession No.
				Identity (%)	QC (%)	
Dihydrofolate reductase (EC 1.5.1.3)	498	51.2	<i>Klebsiella pneumoniae</i> <i>Acinetobacter baumannii</i> <i>E. coli</i>	100	100	CP043863.1 CP027246.2 MN335921.1
Integron integrase <i>IntI1</i>	888	61.1	<i>E. coli</i> <i>Klebsiella pneumoniae</i> <i>Klebsiella variicola</i>	100 97	99.77 99.77	MN218686.1 CP041948.1 CP026014.1
Aminoglycoside 3'-nucleotidyltransferase (EC 2.7.7.-) => ANT(3'')-Ia (AadA family)	780	51.7	<i>Klebsiella pneumoniae</i> <i>E. coli</i> <i>Acinetobacter baumannii</i> <i>E. fergusonii</i>	100	100	CP043863.1 MN335921.1 CP027246.2 CP040806.1
Small multidrug resistance (SMR) efflux transporter)	348	50	<i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i> <i>E. coli</i> <i>Acinetobacter towneri</i>	100	100	CP043863.1 CP039991.1 MN335921.1 CP046045.1
Dihydropteroate synthase type-2 (EC 2.5.1.15)	840	61.6	<i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i> <i>Acinetobacter towneri</i> <i>E. coli</i> <i>Klebsiella variicola</i>	100	100	CP043862.1 MN433457.1 CP046045.1 CP041338.1 CP026014.1
Bleomycin resistance protein	366	60.9	<i>Klebsiella pneumoniae</i> <i>E. coli</i> <i>Klebsiella variicola</i> <i>Acinetobacter towneri</i> <i>Pseudomonas aeruginosa</i>	100	100	CP041949.1 CP041957.1 CP026014.1 CP046045.1 CP024630.1
Subclass B1 beta-lactamase (EC 3.5.2.6) => NDM family	813	61.5	<i>Klebsiella pneumoniae</i> <i>E. coli</i> <i>Acinetobacter baumannii</i> <i>Pseudomonas sp. SKJ15</i>	100	100	CP043863.1 MN197360.1 MN331780.1 MN331784.1
23S rRNA (adenine(2058)-N(6))-dimethyltransferase (EC 2.1.1.184) => Erm(B)	738	33.1	<i>Klebsiella pneumoniae</i> <i>E. coli</i>	100	100	CP043863.1 MN218686.1
Macrolide 2'-phosphotransferase => Mph(A) family	915	65.5	<i>E. coli strain 5M</i> <i>Klebsiella pneumoniae</i>	100	100	MN218686.1 CP043863.1
Class A $\beta$ -lactamase (EC 3.5.2.6) => TEM family	816	49.0	<i>Klebsiella michiganensis</i> <i>Klebsiella pneumoniae strain HKU49</i> <i>Acinetobacter baumannii strain MC75</i> <i>E. fergusonii</i> <i>E. coli strain PE15</i>	100	100	CP024641.1 MN543570.1 MK531541.1 CP040806.1 CP041631.1





**Figure 3** Salient features of *bla*<sub>NDM-5</sub> encoding plasmid pNDM-TC-CE-89 plasmid with other resistance genes, transposons and type IV conjugative transfer system. The circle in red colour indicates the flanking structure of *bla*<sub>NDM-5</sub>. Transfer machinery are showed in green colour. Cloned par loci genes are indicated in yellow colour and the transposons IS26 elements are marked in brown.

topoisomerase IV. In this study, all three isolates displayed mutations in the QRDR region of *gyrA* and *parC*, which has also been reported in many investigations.<sup>30</sup>

The IncFII plasmids are highly mobile and carry several *bla*<sub>NDM</sub> variants in Enterobacteriaceae.<sup>44</sup> A recent study has shown the ability of *bla*<sub>NDM</sub> bearing IncFII plasmid transfer to different members of Enterobacteriaceae along with the other ARGs.<sup>45</sup> In this study, the transfer of pNDM-CE89 carrying *bla*<sub>NDM-5</sub> to other bacteria has been demonstrated along with the expression of MDR. Therefore, commensal *E. coli* having IncFII plasmids with *bla*<sub>NDM-5</sub> are epidemiologically important, as there is a high possibility of its transfer to other pathogens, which will be a major concern in the clinical management of infections.

BLAST-based sequence alignments revealed that the plasmid pNDM-CE-89 had the most similar nucleotide sequences in other plasmids such as pYJ6-NDM5 (accession number AP023236.1) from an *E. coli* strain, pM941-NDM5 (accession number AP023454.1) from an *K. pneumoniae* strain, and pM2\_FII (GenBank accession AP018144.1) from an *E. coli* strain. The plasmid pNDM-CE-89 possesses complex structures as it contains the gene encoding MBLs *bla*<sub>NDM-5</sub>, a large group of genetic elements (integrons, transposons, and ISCRs), *IntI1* (class 1 integron integrase) and *mphA*, a family of macrolide phosphotransferase.

The location of *bla*<sub>NDM-5</sub> in pNDM-CE-89 was identified between the two IS26 elements. The similar flanking genetic structure has previously been observed in other *bla*<sub>NDM-5</sub> bearing plasmids.<sup>33</sup> The IS26 element has been reported in many members of Enterobacteriaceae and exists together with the  $\beta$ -lactamases region, which is a part of transposon-like structure in many plasmids.<sup>46</sup> In pNDM-CE-89, the association of *bla*<sub>NDM-5</sub> with IS26 makes a condition favourable for its mobilization and function. The flanking region of NDM producers carried a highly conserved gene segment (IS26-IS30-*bla*<sub>NDM5</sub>-*ble*<sub>MBL</sub>-*trpF*) suggesting that these four genes are important for the transmission and expression of AMR.

In conclusion, the global dissemination of NDM-producing Gram-negative bacteria is of great concern. Our data suggest that commensal *E. coli* in the gut acts as a reservoir for NDM carrying plasmid and the other ARGs. More epidemiological and clinical studies are needed to elucidate the mechanisms of emergence, evolution and dissemination of NDM-5 in commensal *E. coli* and other gut microbes.

## Ethical Approval

This study was approved by the “Institutional Ethics Committee (IEC) of the National Institute of Cholera and Enteric Diseases in Kolkata, India (registration number: A-1/2015-IEC)”. Written consent was obtained from each adult patient or the parent/guardian of the child patients enrolled in this study.

## Acknowledgment

Dr. Goutam Chowdhury acknowledges the support from Okayama University, Okayama, Japan. TR is a Senior Scientist, Indian National Science Academy, New Delhi, India.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

This study was supported in part by the Indian Council of Medical Research (ICMR), Government of India, New Delhi, India, the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), the Ministry of Education, Culture, Sports, Science and Technology in Japan, and the Japan Agency for Medical Research and Development (AMED; grant number JP21wm0125004 to SM).

## Disclosure

The authors report no conflicts of interest in relation to this work.

## References

1. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence*. 2017;8(4):460–469. doi:10.1080/21505594.2016.1222343
2. Suay-García B, Pérez-Gracia MT. Present and future of carbapenem resistant *Enterobacteriaceae* (CRE) infections. *Antibiotics*. 2019;8:122. doi:10.3390/antibiotics8030122
3. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, *bla*<sub>(NDM-1)</sub>, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*. 2009;53:5046–5054. doi:10.1128/AAC.00774-09
4. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM Metallo- $\beta$ -Lactamases and their bacterial producers in health care settings. *Clin Microbiol Rev*. 2019;32:e00115–e00118. doi:10.1128/CMR.00115-18
5. Basu S. Variants of the New Delhi metallo- $\beta$ -lactamase: new kids on the block. *Future Microbiol*. 2020;15:465–467. doi:10.2217/fmb-2020-0035
6. Hornsey M, Phee L, Wareham DW. A novel variant, NDM-5, of the New Delhi metallo-  $\beta$ -lactamase in a multidrug-resistant *Escherichia coli* ST648 isolate recovered from a patient in the United Kingdom. *Antimicrob Agents Chemother*. 2011;55:5952–5954. doi:10.1128/AAC.05108-11
7. Sassi A, Loucif L, Gupta SK, Dekhil M, Chettibi H, Rolain JM. NDM-5 carbapenemase encoding gene in multidrug-resistant clinical isolates of *Escherichia coli* from Algeria. *Antimicrob Agents Chemother*. 2014;58:5606–5608. doi:10.1128/AAC.02818-13
8. Wailan AM, Paterson DL, Caffery M, Sowden D, Sidjabat HE. Draft Genome Sequence of NDM-5-producing *Escherichia coli* sequence type 648 and genetic context of blaNDM5 in Australia. *Genome Announc*. 2015;3:e00194–e001915. doi:10.1128/genomeA.00194-15

9. Liu Z, Xiao X, Li Y, Liu Y, Li R, Wang Z. Emergence of *incX3* plasmid- harboring *bla<sub>NDM-5</sub>* dominated by *Escherichia coli* ST48 in a goose farm in Jiangsu, China. *Front Microbiol.* 2019;10:2002. doi:10.3389/fmicb.2019.02002
10. Gamal D, Fernández-Martínez M, El-Defrawy I, Ocampo-Sosa AA, Martínez-Martínez L. First identification of NDM-5 associated with OXA-181 in *Escherichia coli* from Egypt. *Emerg Microbes Infect.* 2016;5(1):e30. doi:10.1038/emi.2016.24
11. Rahman M, Shukla SK, Prasad KN, et al. Prevalence and molecular characterisation of New Delhi metallo-β-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India. *Int J Antimicrob Agents.* 2014;44(1):30–37. doi:10.1016/j.ijantimicag.2014.03.003
12. Giufrè M, Errico G, Accogli M, et al. Emergence of NDM-5-producing *Escherichia coli* sequence type 167 clone in Italy. *Int J Antimicrob Agents.* 2018;52(1):76–81. doi:10.1016/j.ijantimicag.2018.02.020
13. Muggeo A, Maiga A, Maiga I, et al. First description of IncX3 NDM-5-producing plasmid within *Escherichia coli* ST448 in Mali. *J Med Microbiol.* 2020;69(5):685–688. doi:10.1099/jmm.0.001182
14. Baek JY, Cho SY, Kim SH, et al. Plasmid analysis of *Escherichia coli* isolates from South Korea co-producing NDM-5 and OXA-181 carbapenemases. *Plasmid.* 2019;104:102417. doi:10.1016/j.plasmid.2019.102417
15. Pitart C, Solé M, Roca I, et al. Molecular Characterization of bla NDM-5 carried on an IncFII Plasmid in an *Escherichia coli* Isolate from a Nontraveler Patient in Spain. *Antimicrob Agents Chemother.* 2015;59(1):659–662. doi:10.1128/AAC.04040-14
16. Rojas LJ, Hujer AM, Rudin SD, et al. NDM- 5 and OXA-181 Beta-Lactamases, a significant threat continues to spread in the Americas. *Antimicrob Agents Chemother.* 2017;61(7):e00454–e00417. doi:10.1128/AAC.00454-17
17. Zou H, Jia X, Liu H, Li S, Wu X, Huang S. Emergence of NDM-5- producing *Escherichia coli* in a Teaching Hospital in Chongqing, China: *incF*-type Plasmids may contribute to the prevalence of *bla<sub>NDM-5</sub>*. *Front Microbiol.* 2020;11:334. doi:10.3389/fmicb.2020.00334
18. Ahmad N, Khalid S, Ali SM, Khan AU. Occurrence of *bla<sub>NDM</sub>* variants among Enterobacteriaceae from a neonatal intensive care unit in a Northern India Hospital. *Front Microbiol.* 2018;9:407. doi:10.3389/fmicb.2018.00407
19. Paitan Y. Current trends in antimicrobial resistance of *Escherichia coli*. *Curr Top Microbiol Immunol.* 2018;416:181–211. doi:10.1007/82\_2018\_110
20. Ceccarelli D, Hesp A, van der GJ, et al. Antimicrobial resistance prevalence in commensal *Escherichia coli* from broilers, fattening turkeys, fattening pigs and veal calves in European countries and association with antimicrobial usage at country level. *J Med Microbiol.* 2020;69:537–547. doi:10.1099/jmm.0.001176
21. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis.* 2010;10(9):597–602. doi:10.1016/S1473-3099(10)70143-2
22. Gidudu J, Sack DA, Pina M, et al. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine.* 2011;29(5):1053–1071. doi:10.1016/j.vaccine.2010.11.065
23. Nair GB, Ramamurthy T, Bhattacharya MK, et al. Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India. *Gut Pathog.* 2010;2(1):4. doi:10.1186/1757-4749-2-4
24. Panchalingam S, Antonio M, Hossain A, et al. Diagnostic microbiologic methods in the GEMS-1 case/control study. *Clin Infect Dis.* 2012;55(suppl\_4):S294–S302. doi:10.1093/cid/cis754
25. Hinenoya A, Ichimura H, Yasuda N, et al. Development of a specific cytolethal distending toxin (*cdt*) gene (Eactd)-based PCR assay for the detection of *Escherichia albertii*. *Diagn Microbiol Infect Dis.* 2019;95:119–124. doi:10.1016/j.diagmicrobio.2019.04.018
26. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
27. Ribot EM, Fair MA, Gautom R, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of *Escherichia coli* O157: H7, *Salmonella*, and *Shigella* for PulseNet. *Foodborne Pathog Dis.* 2006;3:59–67. doi:10.1089/fpd.2006.3.59
28. Wirth T, Falush D, Lan R, et al. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol.* 2006;60(5):1136–1151. doi:10.1111/j.1365-2958.2006.05172.x
29. Chowdhury G, Ramamurthy T, Ghosh A, Dutta S, Takahashi E, Mukhopadhyay AK. Emergence of azithromycin resistance mediated by phosphotransferase-Encoding *mph* (A) in diarrheagenic *Vibrio fluvialis*. *mSphere.* 2019;4(3):e00215–e00219. doi:10.1128/mSphere.00215-19
30. Rawat N, Jamwal R, Devi PP, et al. Detection of unprecedented level of antibiotic resistance and identification of antibiotic resistance factors, including QRDR mutations in *Escherichia coli* isolated from commercial chickens from North India. *J Appl Microbiol.* 2021;10. doi:10.1111/jam.15209
31. Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. *J Bacteriol.* 1981;145(3):1365–1373. doi:10.1128/jb.145.3.1365-1373.1981
32. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods.* 2005;63(3):219–228. doi:10.1016/j.mimet.2005.03.018
33. Sugawara Y, Akeda Y, Sakamoto N, et al. Genetic characterization of *bla<sub>NDM</sub>*-harboring plasmids in carbapenem-resistant *Escherichia coli* from Myanmar. *PLoS One.* 2017;12:e0184720. doi:10.1371/journal.pone.0184720
34. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. *Clin Infect Dis.* 2019;69:S521–S528. doi:10.1093/cid/ciz824
35. Thanh DP, Thi Nguyen TN, Vu TD, et al. Commensal *Escherichia coli* are a reservoir for the transfer of XDR plasmids into epidemic fluoroquinolone-resistant *Shigella sonnei*. *Nat Microbiol.* 2020;5(2):256–264. doi:10.1038/s41564-019-0645-9
36. Baloch Z, Lv L, Yi L, et al. Emergence of almost identical F36: a-β32 Plasmids carrying *bla<sub>NDM-5</sub>* and *qepA* in *Escherichia coli* from Both Pakistan and Canada. *Infect Drug Resist.* 2019;12:3981–3985. doi:10.2147/IDR.S236766
37. Marchetti VM, Bitar I, Mercato A, et al. Complete nucleotide sequence of plasmids of two *Escherichia coli* Strains carrying and *bla<sub>NDM-5</sub>* and *bla<sub>OXA-181</sub>* from the same patient. *Front Microbiol.* 2020;10:3095. doi:10.3389/fmicb.2019.03095
38. Krishnaraju M, Kamatchi C, Jha AK, et al. Complete sequencing of an IncX3 plasmid carrying *bla<sub>NDM-5</sub>* allele reveals an early stage in the dissemination of the *bla<sub>NDM</sub>* gene. *Indian J Med Microbiol.* 2015;33:30–38. doi:10.4103/0255-0857.148373
39. Paul D, Garg A, Bhattacharjee A. Occurrence of *bla<sub>NDM-1</sub>* and *bla<sub>NDM-5</sub>* in a tertiary referral hospital of North India. *Microb Drug Resist.* 2017;23:815–821. doi:10.1089/mdr.2016.0124

40. Hammerum AM, Littauer P, Hansen F. Detection of *Klebsiella pneumoniae* co-producing NDM-7 and OXA-181, *Escherichia coli* producing NDM-5 and *Acinetobacter baumannii* producing OXA-23 in a single patient. *Int J Antimicrob Agents*. 2015;6:597–598. doi:10.1016/j.ijantimicag.2015.07.008
41. Ghatak S, Singha A, Sen A, et al. Detection of New Delhi Metallo-beta-Lactamase and Extended-Spectrum beta-lactamase genes in *Escherichia coli* isolated from mastitic milk samples. *Transbound Emerg Dis*. 2013;60(5):385–389. doi:10.1111/tbed.12119
42. Singh AS, Lekshmi M, Nayak BB, Kumar SH. Isolation of *Escherichia coli* harboring *bla*<sub>NDM-5</sub> from fresh fish in India. *J Microbiol Immunol Infect*. 2016;49(5):822–823. doi:10.1016/j.jmii.2014.11.004
43. Yang RS, Feng Y, Lv XY, et al. Emergence of NDM-5- and MCR-1-producing *Escherichia coli* Clones ST648 and ST156 from a single muscovy duck (*Cairina moschata*). *Antimicrob Agents Chemother*. 2016;60:6899–6902. doi:10.1128/AAC.01365-16
44. Yang L, Lin Y, Lu L, et al. Coexistence of Two *bla*<sub>NDM-5</sub> genes carried on IncX3 and IncFII plasmids in an *Escherichia coli* isolate revealed by illumina and nanopore sequencing. *Front Microbiol*. 2020;11:195. doi:10.3389/fmicb.2020.00195
45. Takayama Y, Sekizuka T, Matsui H, et al. Characterization of the IncFII-IncFIB (pB171) plasmid carrying *bla*<sub>NDM-5</sub> in *Escherichia coli* ST405 clinical isolate in Japan. *Infect Drug Resist*. 2020;13:561–566. doi:10.2147/IDR.S232943
46. Sarkar A, Pazhani GP, Chowdhury G, Ghosh A, Ramamurthy T. Attributes of carbapenemase encoding conjugative plasmid pNDM-SAL from an extensively drug-resistant *Salmonella enterica* Serovar Senftenberg. *Front Microbiol*. 2015;6:969. doi:10.3389/fmicb.2015.00969

## Infection and Drug Resistance

Dovepress

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>